The Center for Breakthrough Medicines, an advanced therapy CDMO partner in the industry servicing pre-clinical to commercial phase therapies, announced on Thursday that it has named Joerg Ahlgrimm as its new chief executive officer.

Ahlgrimm has more than 20 years of expertise in the areas of operations and supply chain management and has served in multi-billion-dollar companies operating in biotech, vaccines, pharmaceutical and medical device markets. He was head of Global Operations Pharma Biotech and Nutrition at Lonza and head of Global Manufacturing for Baxter Healthcare's BioScience Division, Baxalta Inc. He joined CBM as chief operating officer.

Audrey Greenberg, co-founder, Center for Breakthrough Medicines, said, 'We are thrilled about Joerg's appointment to CEO. Joerg's 'team player' mentality, ability to roll up his sleeves, and deep industry relationships will be a game changer for CBM and the advanced therapies industry. Joerg has a proven ability to execute on large-scale projects. Joerg's extraordinary achievements for the pharma, biotech, and CDMO industries combined with his incredible leadership, makes him the ideal choice to head our executive management team and build CBM into an advanced therapy powerhouse.'